Rojukiss International Public Company Limited

Rojukiss International Public Company Limited

KISS.BK
Rojukiss International Public Company LimitedTH flagStock Exchange of Thailand
3.70
THB
+0.02
- -
2.16BMarket Cap
Rojukiss International Public Company Limited
KISS.BK
(Stock Exchange of Thailand)

Recent

price

3.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
31.97
42.15
1.79
1.3
1.55
1.61
1.95
2.03
2.19
Revenue per Share
- -
3.92
7.04
0.31
0.2
0.21
0.22
0.27
0.28
0.3
Basic EPS, GAAP
- -
-0.94
7.3
0.48
0.3
0.14
0.01
0.23
0.33
0.4
Free Cash Flow per Basic Share
- -
- -
9.26
0.36
0.23
0.16
0.14
0.28
0.28
0.24
Dividend per Share
- -
14.78
11.92
0.7
0.66
0.69
0.77
0.7
0.68
0.76
Book Value per Share
- -
15.11
12.93
0.78
1.56
1.67
1.79
1.69
1.69
1.77
Tangible Book Value per Share
- -
27
27
540
592
600
600
600
593
591
Basic Weighted Avg Shares
- -
863
1,138
965
772
932
965
1,169
1,207
1,293
Sales/Revenue/Turnover
- -
15.91
20.37
24.34
18.45
17.96
19.88
16.56
17.95
17.86
Operating Margin (%)
- -
9
11
14
14
17
19
19
14
13
Depreciation Expense
- -
106
190
168
119
124
131
160
165
175
Net Income, GAAP
- -
18.28
18.55
24.2
19.05
18.32
21.09
19.92
25.34
25.47
Effective Tax Rate (%)
- -
12.26
16.71
17.41
15.35
13.27
13.62
13.66
13.71
13.56
Profit Margin (%)
309
343
265
326
858
984
1,022
965
959
1,004
Working Capital
80
12
8
10
2
31
7
4
2
7
LT Debt
313
418
357
428
930
1,019
1,093
1,019
1,007
1,054
Total Equity
- -
22.3
34.48
29.77
14.53
13.87
13.59
14.06
15.87
16
Return on Invested Capital (%)
- -
22.36
36.2
30.46
23.77
21.33
18.85
29.6
39.84
38.14
Return on Capital (%)
- -
29.96
52.76
47.9
30.89
30.84
30
36.33
40.34
38.86
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
4
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
585
585
585
Market Capitalization
1,646
1,801
1,940

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,129
1,225
1,323
Cash, Cash Equivalents & STI
295
380
476
Accounts Receivable, Net
382
434
437
Inventories
217
171
181
Total Current Liabilities
226
266
319
Payables & Accruals
209
253
307
ST Debt
2
2
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.27%
-1.19%
Free Cash Flow
- -
827.44%
44.6%
Net Income, GAAP
- -
1.25%
3.58%
Sales/Revenue/Turnover
- -
5.73%
3.21%
Total Cash Common Dividend
- -
5.13%
-3.77%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
213
309
301
347
1,169
2025
245
268
330
365
1,207
2026
331
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.06
0.09
- -
0.27
2025
0.06
0.04
0.1
- -
0.28
2026
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.09
0.1
- -
0.28
2025
0.04
0.14
0.1
- -
0.28
2026
- -
- -
- -
- -
- -
Business
Rojukiss International Public Company Limited operates primarily in the health and beauty sector, manufacturing and distributing skin care products, color cosmetics, and food supplements. The company markets these products under various brands in both domestic and international markets, including Laos, Cambodia, Indonesia, Vietnam, and Thailand. Its products include face masks, facial moisturizers, skincare treatments such as Reju PDRN essence and Phyto-Retinol, hydrogel masks, micellar water, pore bright cream with SPF 50, B12 skin barrier cream, and wrapping masks. Founded in 2007 and headquartered in Bangkok, Thailand, Rojukiss emphasizes innovation and dermatological expertise to meet evolving consumer needs. Recent major developments include the launch of the "Rojukiss Skin Lab," an innovation center established in collaboration with strategic OEM partners to reinforce the company's R&D capabilities and dermatological product development. The company has expanded its geographic footprint by appointing official distributors and operational systems in Vietnam, Laos, Cambodia, and other Southeast Asian markets, aiming to grow international revenue from 2% to 5% by the end of 2025, with a long-term target of 20% by 2030. Additionally, Rojukiss has increased its product launch pace with new offerings such as serum treatment pads, sleeping masks, and extended product lines in collagen peptide and vitamin formulations. It also concluded a strategic collaboration on direct-to-consumer (D2C) strategies with Sasin School of Management and MIT Sloan School of Management to enhance consumer engagement and market responsiveness. The company maintains strong market leadership in the face mask segment, with a market share increase to 18.2% as of 2Q25 and continued sell-out growth in semi-credit customers and e-commerce channels. Its financial performance shows solid revenue generation supported by efficiency improvements in supply chain and inventory management, despite challenges such as retailer inventory adjustments. Rojukiss continues to pursue growth through clinically backed skincare innovation, impactful marketing, and elevated packaging design while leveraging a multi-channel distribution model covering direct country management, distributor-led approaches in critical markets, and wholesale expansion globally. This comprehensive approach positions Rojukiss International as a leading player in Asia’s health and beauty sector advancing through innovation and regional expansion.